NEWSROOM | Galderma

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

Galderma launches CETAPHIL® line for sensitive skin and a new DAYLONG® sun protection product in Switzerland

New study reveals the impact of ‘hidden acne’ on quality of life

Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases

Galderma acts on workplace health and safety

#RosaceaUnmasked by Galderma unites the rosacea community to shine light on the impact of essential COVID-19 mask-wearing this Rosacea Awareness Month

Galderma announces publication of phase 2b trial results demonstrating the rapid and long-lasting benefits of nemolizumab in clinical trial subjects with uncontrolled atopic dermatitis

Unveiling the new Galderma!

Galderma online survey reveals almost two thirds of rosacea patients* are experiencing worsening of signs and symptoms related to essential COVID-19 mask wearing

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe

Galderma receives FDA approval for Restylane® Defyne for chin augmentation